Oncology clinical pathways and clinical decision support (CDS) tools have been part of the oncology landscape in one form or another for many years. Pathways are increasingly common and can assist providers in navigating the increasingly complex set of treatment selections.
Our recent column highlights HMP Market Access Insights’ (MAI) research on oncologists’ awarenesses of pathways and the factors driving adoption. Our 2023 Oncology Clinical Pathways study focused on quantifying the influence and impact pathways have on oncologists’ treatment decisions by conducting a unique two-arm study with 132 oncologists using advanced conjoint analysis. Key findings include:
Welcome to the April 2024 edition of our Monthly Insight Series. This month we’re looking at community oncology practices’ reliance on buy-and-bill drug revenues.
Lee BlansettNavigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.
Emma BijesseWelcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.
Taylor Crutison